Protocol Ledger

NCT06951217 · Phase II · RECRUITING

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Interventional Phase II clinical trial protocol NCT06951217 sponsored by Avalyn Pharma in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-17 Enrollment: 340 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06951217
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)340 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06951217
Protocol FieldVerified Registry Value
NCT IdentifierNCT06951217
Consolidated Lead SponsorAvalyn Pharma
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment340 participants (ESTIMATED)
Registered Start Date2025-04-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI